8-溴-1-萘甲酸 | 1729-99-3

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 8-溴-1-萘甲酸
• 中文别名: 8-溴-1-萘酸
• 英文名称: 8-bromonaphthalene-1-carboxylic acid
• 英文别名: 8-bromo-1-naphthoic acid；8-Brom-naphthoesaeure-(1)；8-Brom-[1]naphthoesaeure；1-bromo-8-naphthoic acid
• CAS: 1729-99-3
• 化学式: C₁₁H₇BrO₂
• mdl: MFCD00029357
• 分子量: 251.079
• InChiKey: DMEZDDHJCUHENA-UHFFFAOYSA-N

物化性质

• 熔点：
  162-164
• 沸点：
  421.2±18.0 °C(Predicted)
• 密度：
  1.648±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	8-Bromo-1-naphthoic acid 97% Material Safety Data Sheet
Synonym:
CAS:	1729-99-3

Section 1 - Chemical Product MSDS Name:8-Bromo-1-naphthoic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1729-99-3	8-Bromo-1-naphthoic acid	97%	217-045-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1729-99-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 162 - 164 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H7BrO2
Molecular Weight: 251

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1729-99-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
8-Bromo-1-naphthoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1729-99-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1729-99-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1729-99-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  8-溴-1-萘甲酸 在 N-氯代丁二酰亚胺 、 lithium aluminium tetrahydride 、 氯化亚砜 、 二甲基硫 、 三乙胺 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 15.5h， 生成 8-(methylthio)-1-naphthaldehyde
  参考文献：
  名称：

  8-取代的 1-萘亚甲基和 2-取代的亚苄基的化学。1H-环丁[de]萘的简单入门

  摘要：

  关于研究 d'unheteroatome dans la hotlyse et la photolyse d'aryldiazomethane substitues

  DOI：

  10.1021/ja00357a021
• 作为产物：
  描述：

  O-(hydroxymercuri)-1-naphtoic acid anhydride 在 溶剂黄146 、 溴 、 sodium bromide 作用下， 以 水 为溶剂， 反应 0.17h， 以84%的产率得到8-溴-1-萘甲酸
  参考文献：
  名称：

  Synthesis and pharmacology of 1-alkyl-3-(1-naphthoyl)indoles: Steric and electronic effects of 4- and 8-halogenated naphthoyl substituents

  摘要：

  To develop SAR at both the cannabinoid CB1 and CB2 receptors for 3-(1-naphthoyl)indoles bearing moderately electron withdrawing substituents at C-4 of the naphthoyl moiety, 1-propyl and 1-pentyl-3-(4-fluoro, chloro, bromo and iodo-1-naphthoyl) derivatives were prepared. To study the steric and electronic effects of substituents at the 8-position of the naphthoyl group, the 3-(4-chloro, bromo and iodo-1-naphthoyl) indoles were also synthesized. The affinities of both groups of compounds for the CB1 and CB2 receptors were determined and several of them were evaluated in vivo in the mouse. The effects of these substituents on receptor affinities and in vivo activity are discussed and structure-activity relationships are presented. Although many of these compounds are selective for the CB2 receptor, only three JWH-423, 1-propyl-3-(4-iodo-1-naphthoyl)indole, JWH-422, 2-methyl-1-propyl-3-(4-iodo-1-naphthoyl) indole, the 2-methyl analog of JWH-423 and JWH-417, 1-pentyl-3-(8-iodo-1-naphthoyl)indole, possess the desirable combination of low CB1 affinity and good CB2 affinity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.038

文献信息

• Palladium-Catalyzed Domino Heck/C–H Activation/Decarboxylation: A Rapid Entry to Fused Isoquinolinediones and Isoquinolinones
  作者：Xiai Luo、Liwei Zhou、Haiyan Lu、Guobo Deng、Yun Liang、Chunming Yang、Yuan Yang

  DOI：10.1021/acs.orglett.9b03883

  日期：2019.12.20

  A new palladium-catalyzed tandem cyclization of various alkene-tethered aryl iodides has been presented. In this protocol, o-bromobenzoic acids are employed as coupling parters to achieve the insertion of aromatic rings by the cleavage of C(sp2)-Br and decarboxylation, thus assembling various dibenzoisoquinolinediones and dibenzoisoquinolinones. In addition, a seven-membered ring can be constructed

  提出了一种新的钯催化串联环化各种烯烃系芳基碘化物的方法。在该协议中，邻溴苯甲酸用作偶联剂，通过C（sp2）-Br的裂解和脱羧作用实现芳香环的插入，从而组装各种二苯并异喹啉二酮和二苯并异喹啉酮。另外，可以通过使用8-溴-1-萘甲酸来构建七元环。值得注意的是，这种方法能够形成区域选择性的产物并具有广泛的底物范围。
• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2018183781A1

  公开（公告）日：2018-10-04

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

  提供的是化合物、包含该化合物的药物组合物、制备该化合物的方法，以及使用该化合物和组合物治疗与电压门控钠通道功能相关的病症的方法，其中所述化合物是根据公式(I)的11,13-修饰的石房蛤毒素：其中R4、R4a、R7、R7a和X2如本文所述。
• Palladium-Catalyzed [4 + 3] or [2 + 2 + 3] Annulation via C–H Activation and Subsequent Decarboxylation: Access to Heptagon-Embedded Polycyclic Aromatic Hydrocarbons
  作者：Xiumei Yang、Xiahong Chen、Yankun Xu、Minghao Zhang、Guobo Deng、Yuan Yang、Yun Liang

  DOI：10.1021/acs.orglett.1c00520

  日期：2021.4.2

  attractive challenge. Herein a novel palladium-catalyzed [4 + 3] decarboxylative annulation of 2-iodobiphenyls with 2-(2-halophenyl)acrylic acids is reported, which provides an efficient approach for assembling various tribenzo[7]annulenes via a C–H activation and decarboxylation process. Moreover, tribenzo[7]annulenes can be also synthesized via a [2 + 2 + 3] decarboxylative annulation strategy by employing

  在多环芳烃骨架中构造七元环仍然是一个众所周知的难题，但仍是一个有吸引力的挑战。本文报道了一种新颖的钯催化2-碘联苯与2-（2-卤代苯基）丙烯酸的[4 ​​+ 3]脱羧环化反应，它提供了一种通过C–H活化和组装各种三苯并[7]环烯的有效方法。脱羧过程。而且，三苯并[7]环戊烯还可以通过[2 + 2 + 3]脱羧环化策略，通过使用容易获得的1,2-卤代苯，苯基硼酸和2-（2-卤代苯基）丙烯酸来合成。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES MODIFIÉES 11,13 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2020072835A1

  公开（公告）日：2020-04-09

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

  本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法，以及在治疗与电压门控钠通道功能相关的疾病中使用该化合物和组合物的方法，其中该化合物是根据式(I)的11,13-修饰沙雌毒素：(式(I))；其中R1和R2如本文所述。

表征谱图